Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.

Register for Details

For more details on financing and valuation of private companies similar to Alumis before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Alumis

To invest in Alumis pre-IPO

Can you invest in Alumis pre-IPO?

You may invest in Alumis as it is a public company listed on the NASDAQ with ticker ALMS. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Alumis before it goes public?

You can no longer sell shares of Alumis on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Alumis shares?

Forge can no longer determine the value of Alumis shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Alumis a publicly traded company?

Alumis became a public company following its IPO on 06/28/2024 and is now traded on the NASDAQ under the ticker ALMS.

To learn more about Alumis potential IPO

Will Alumis go IPO?

Alumis became a public company following its IPO on 06/28/2024 and is now traded on the NASDAQ under the ticker ALMS.

What is Alumis’ IPO price?

The IPO price of Alumis is not currently available.

When was Alumis founded?

Alumis was founded in 2021.

What is Alumis funding to date?

Alumis has raised $1.66B to date.

Who are Alumis’s major investors?

Foresite Capital
Cormorant Asset Management
Ally Bridge Group
Samsara Biocapital
venBio
Lilly Asia Ventures
Piper Sandler
HBM Healthcare Investments
SR One Capital Management
Omega Funds
Matrix Capital Management
NexTech

Alumis Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/06/2024 Series C-1 $4.00 $xx.xx $702.67MM Ally Bridge Group, Ayurmaya, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
Price per Share
$xx.xx
Shares Outstanding
1
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Ayurmaya, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
03/06/2024 Series C $259MM $xx.xx $702.67MM Ally Bridge Group, Ayurmaya Capital Management, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
Price per Share
$xx.xx
Shares Outstanding
82,529,809
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Ayurmaya Capital Management, Cormorant Asset Management, Foresite Capital, Hbm Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare, Samsara Biocapital, Sr One, Venbio Partners
05/08/2023 Series B-2 $90MM $xx.xx $607.01MM Ayurmaya Capital Management, Foresite Capital
Price per Share
$xx.xx
Shares Outstanding
18,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ayurmaya Capital Management, Foresite Capital
05/08/2023 Series B-2A $8.89MM $xx.xx $607.01MM Ayurmaya Capital Management, Foresite Capital
Price per Share
$xx.xx
Shares Outstanding
1,778,830
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ayurmaya Capital Management, Foresite Capital
01/06/2022 Series B $201MM $xx.xx $483.98MM Matrix Capital Management
Price per Share
$xx.xx
Shares Outstanding
40,200,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Matrix Capital Management
05/05/2021 Series A $30MM $xx.xx $185.07MM Foresite Capital
Price per Share
$xx.xx
Shares Outstanding
7,500,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital
05/05/2021 Series B-1 $39.04MM $xx.xx $185.07MM Foresite Capital
Price per Share
$xx.xx
Shares Outstanding
9,760,088
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital
01/29/2021 Series Seed $10.5MM $xx.xx $23.33MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
10,500,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.